Volume : 13, Issue : 10, October – 2026
Title:
FORMULATION AND IN VITRO EVALUATION BRIVARACETAM SUSTAINED RELEASE TABLET
Authors :
A. Saritha*, T Nandini
Abstract :
The present study was aimed at the formulation and evaluation of Brivaracetam sustained-release (SR) matrix tablets using the wet granulation method to achieve prolonged drug release and improve patient compliance by reducing dosing frequency. Brivaracetam, a third-generation antiepileptic drug with a relatively short half-life, was selected as the model drug for sustained-release formulation. Eight formulations (F1–F8) were prepared by incorporating different concentrations of sodium alginate and tragacanth as release-retarding polymers while maintaining a constant tablet weight of 400 mg. The in vitro dissolution study showed a controlled and sustained release of Brivaracetam over 8 hours, with cumulative drug release ranging from 92.53% to 97.58%. Among the prepared formulations, F6 demonstrated the highest cumulative drug release (97.58%) and was selected as the optimized formulation. The dissolution data of the optimized formulation were fitted to various kinetic models. Stability studies conducted under 25°C/60% RH, 30°C/75% RH, and 40°C/75% RH for three months revealed no significant changes in the physical appearance or dissolution profile of the optimized formulation, confirming its stability under the tested storage conditions. Overall, the study demonstrated that tragacanth-based formulation F6 is a promising sustained-release matrix tablet of Brivaracetam capable of providing controlled drug release with good stability.
Keywords: Brivaracetam, Sustained-release tablets, Wet granulation, Sodium alginate, Tragacanth, Matrix tablets, Drug release kinetics, Stability studies.
Cite This Article:
Please cite this article in press A. Saritha et al., Formulation And In Vitro Evaluation Brivaracetam Sustained Release Tablet.,. Indo Am. J. P. Sci, 2026; 13(10).
REFERENCES:
1. Mathew AV, Rampal V, Jose A, et al. Brivaracetam: a novel antiepileptic drug for the treatment of partial-onset seizures. Journal of Pharmacy and Bioallied Sciences. 2016;8(1):1-6.
2. Ben-Menachem E. Brivaracetam: a novel antiepileptic drug with a unique mechanism of action. Epilepsy Research. 2010;89(1):1-7.
3. Kenda BM, Matagne AC, Talaga PE, et al. Discovery of brivaracetam, a selective high-affinity ligand for synaptic vesicle protein 2A. Journal of Medicinal Chemistry. 2004;47(21):5308-5319.
4. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 2004;5(7):553-564.
5. Gillard M, Fuks B, Michel P, et al. Binding characteristics of brivaracetam to synaptic vesicle protein 2A and its anticonvulsant properties. Epilepsia. 2011;52(12):2321-2330.
6. Klein P, Schiemann J, Sperling MR, et al. Brivaracetam for the treatment of uncontrolled partial-onset seizures in epilepsy. Neurology. 2015;85(11):945-952.
7. Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57-66.
8. Ben-Menachem E, French JA, Kwan P, et al. Efficacy and safety of brivaracetam for partial-onset seizures: a systematic review. Epilepsy & Behavior. 2016;62:56-62.
9. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine. 2000;342(5):314-319.
10. Vongluecha P, Pattanawongsa A, Suksiriworapong J, et al. Oral sustained-release drug delivery systems: formulation approaches and evaluation. Drug Development and Industrial Pharmacy. 2018;44(8):1259-1271.
11. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharmaceutical Science & Technology Today. 2000;3(6):198-204.
12. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Advanced Drug Delivery Reviews. 1993;11(1-2):37-57.
13. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews. 2012;64:163-174.
14. Colombo P, Bettini R, Massimo G, Catellani PL, Santi P, Peppas NA. Drug diffusion front movement is important in drug release control from HPMC matrices. Journal of Pharmaceutical Science. 1995;84(8):991-997.
15. Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery. Journal of Controlled Release. 2012;163(2):121-134.
16. Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. Journal of Controlled Release. 2011;154(1):2-19.